GPC3 and hepatocellular carcinoma: Additionally, GPC3 (144–152) peptide vaccine can induce high avidity CTLs capable of killing hepatocellular carcinoma (HCC) cells expressing GPC3 that may be used for HCC immunotherapy [31].